UPDATE: Piper Jaffray Raises PT to $27 on Pacira Pharmaceuticals on Strong Exparel Data Points

Loading...
Loading...
Piper Jaffray reiterated its Overweight rating on Pacira Pharmaceuticals
PCRX
and raised the price target from $22.00 to $27.00. Piper Jaffray noted, “Data points for Pacira's Exparel continue to look favorable, reinforcing our confidence in a strong sales ramp for 2013 and beyond. Institutional sales (wholesale acquisition cost (WAC)-based sales, per Wolters Kluwer (WK), via Bloomberg) for Exparel for December 2012 were around $2.76M, compared to $1.67M in November. Though third party sources generally have done an uneven job of capturing demand, the directional trends dovetail with PCRX's bullish commentary regarding hospital acceptance. We remain confident in our Exparel sales estimates of $70M and $146M in 2013 and 2014, respectively.” Pacira Pharmaceuticals closed at $19.88 on Friday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetIntraday UpdateAnalyst RatingsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...